ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology

Rhea-AI Summary

ADC Therapeutics (NYSE:ADCT) announced that the Phase 1 clinical trial results of its anti-CD25 ADC, camidanlumab tesirine (Cami), have been published in The Lancet Haematology. The trial, involving 133 patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas, reported an overall response rate (ORR) of 58%, with a complete response rate of 29%. Heavily treated Hodgkin lymphoma patients showed an ORR of 71%. The study indicates Cami's potential as a treatment option for a significant unmet medical need. A pivotal Phase 2 trial is ongoing.

Positive

• Published Phase 1 trial results in The Lancet Haematology highlight Cami's potential.
• Overall response rate of 58%, with 29% achieving a complete response.
• For Hodgkin lymphoma, the overall response rate was 71%, demonstrating strong efficacy.
• Cami showed an acceptable safety profile with no new safety signals reported during clinical trials.

Negative

• The overall response rate for non-Hodgkin lymphoma patients was only 38%, indicating limited efficacy.
• No new safety signals were reported, but common adverse events like elevated liver enzymes could raise concerns.

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of the Phase 1 clinical trial of camidanlumab tesirine (Cami), an anti-CD25 ADC, in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas have been published online in The Lancet Haematology.

“There is a significant unmet medical need for novel therapies that improve outcomes in patients with relapsed or refractory Hodgkin lymphoma,” said Mehdi Hamadani, MD, Professor of Internal Medicine at the Medical College of Wisconsin, Division of Hematology & Oncology and lead author of The Lancet Haematology paper. “This patient population is often heavily pretreated, as was the case in this published study in which patients experienced a median of five previous systemic therapies. The Phase 1 study demonstrates encouraging potential for Cami to provide a new treatment option for patients with relapsed or refractory Hodgkin lymphoma.”

The multicenter, open-label, single-arm, dose escalation and dose expansion Phase 1 clinical trial enrolled 133 adult patients, 77 (58%) with classical Hodgkin lymphoma and 56 (42%) with non-Hodgkin lymphoma. Enrolled patients were required to have pathologically confirmed relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma and no therapies with established clinical benefit for their disease stage available to them.

“We’re pleased the results of our Phase 1 trial of Cami in patients with relapsed or refractory lymphoma have been published in The Lancet Haematology,” said Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer at ADC Therapeutics. “The positive results in patients with Hodgkin lymphoma guided the design of our pivotal Phase 2 trial, which has completed enrollment. We’re continuing to follow patients and look forward to presenting data from the Phase 2 Cami trial at an upcoming congress.”

Key results include:

• In the total patient population, the overall response rate (ORR) was 58%, with 38 (29%) of 130 patients reported to have a complete response.
• In heavily pretreated patients with Hodgkin lymphoma, across all doses, the ORR was 71%, with 32 (42%) of 77 patients reported to have a complete response.
  • In Hodgkin lymphoma patients who received 45 μg/kg (the recommended Phase 2 starting dose), the ORR was 86%, with 18 (49%) of 37 patients reported to have a complete response.
  • In Hodgkin lymphoma patients who received 30 μg/kg, the ORR was 55%, with seven (35%) of 20 patients reported to have a complete response.
• In patients with non-Hodgkin lymphoma, the ORR was 38%, with five (9%) of 53 patients reported to have a complete response.
• The overall median duration of response was 6.6 months for all patients with Hodgkin lymphoma and 7.2 months for Hodgkin lymphoma patients who received 45 μg/kg.
• Cami demonstrated an acceptable safety profile. The most commonly observed adverse events included elevated liver enzymes (without hepatic synthetic dysfunction), rash, fatigue, oedema or effusion, and nausea.

Based on the data from this Phase 1 clinical trial, a Phase 2 trial to further evaluate the safety and efficacy of Cami in patients with relapsed or refractory Hodgkin lymphoma is ongoing. Interim data from the pivotal Phase 2 trial presented at the 2020 American Society of Hematology meeting demonstrated encouraging antitumor activity as a single agent with an ORR of 83%, a complete response rate of 38% and no new safety signals. These data highlight the potential for Cami to address an unmet need in heavily pretreated patients (median of seven prior lines of systemic therapy).

For information about the ongoing pivotal Phase 2 clinical trial of Cami in patients with relapsed or refractory Hodgkin lymphoma, please visit https://clinicaltrials.gov/ (identifier NCT04052997).

About Camidanlumab Tesirine (Cami)

Camidanlumab tesirine (Cami, formerly ADCT-301) is an antibody drug conjugate (ADC) comprised of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload, tesirine. Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload, killing the cell. This applies to CD25-expressing tumor cells and also to CD25-expressing Tregs. The intra-tumoral release of its PBD payload may also cause bystander killing of neighboring tumor cells, and PBDs have also been shown to induce immunogenic cell death. All of these properties of Cami may enhance immune-mediated anti-tumor activity.

Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA™ (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, the Company has multiple PBD-based ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005542/en/

FAQ

What are the key findings of the Phase 1 trial for ADCT's camidanlumab tesirine?

The Phase 1 trial showed an overall response rate of 58%, with 29% of patients achieving a complete response, particularly noting a 71% response in heavily pretreated Hodgkin lymphoma patients.

What is the significance of the publication of the Phase 1 trial results for ADCT?

The publication in The Lancet Haematology validates the clinical findings and supports the ongoing development of Cami as a treatment for relapsed or refractory Hodgkin lymphoma.

What are the next steps for the Cami trial after the Phase 1 results?

ADC Therapeutics is advancing to a pivotal Phase 2 clinical trial to further evaluate Cami’s safety and efficacy in patients with relapsed or refractory Hodgkin lymphoma.

What safety profile did Cami demonstrate in the Phase 1 trial?

Cami exhibited an acceptable safety profile, with the most common adverse events being elevated liver enzymes, fatigue, and nausea, without new safety signals.

How does the response rate for Cami compare between Hodgkin and non-Hodgkin lymphoma patients?

The overall response rate for Hodgkin lymphoma patients was significantly higher at 71%, compared to just 38% for non-Hodgkin lymphoma patients in the Phase 1 trial.